From: Boris Nikolic
To: Gene Walther ,
CC: ehud barak
Subject: FW: Parasight Ltd.
Date: Mon, 12 Aug 2013 04:40:53 +0000
Attachments: PARASIGHT_EXECUTIVE_SUMMARY_V1.8.pdfi ATT00001.htm; CL-
IN002_Report_signed.pdf; ATT00002.htm
Thank you Ehud!
We will follow up for sure.
I am sending this to Gene Walther who is leading diagnostics (including malaria diagnostics) at Bill and Melinda Gates
Foundation.
I think that Gene is on business travel and vacation right now so it might be some delay.
Looking forward to learning more re this promising technology!
All the best
Boris
From: thud barak [milt°
Sent: Sunday, August 11, 2013 9:51 AM
To: Boris Nikolic
Subject: Fwd: Parasight Ltd.
Dear Boris
Attached as promised p1 find Parasight presentation.
PI send me your initial response and we'll consider how to continue \A ith them.
Best
Ehud Barak
Sent from my iPhone
Begin forwarded message:
From: Doron
Date: August 11, 2013 18:52:33 GMT+03:00
To: Ehud BARAK
Subject: Fwd: Parasight Ltd.
EFTA00967515
Dear Dr. Nikolic,
Parasight Ltd was founded two years ago in Israel in order to develop a platform technology for
blood analysis and parasite detection. During this time, Parasight has focused on developing an
innovative device for the accurate, rapid and inexpensive diagnosis of Malaria, suitable for POC and
labs in Malaria-endemic countries as well as blood banks everywhere. The device is based on the
latest technologies in the field of machine-vision together with breakthrough advances in sample
preparation and staining.
Following Mr. Barak's communication with you, we are proud to present the official report
describing the results of our first clinical trial, which was conducted recently in India by the
National Institute of Malaria Research. As the report indicates, our clinical accuracy is on par with
PCR, but with ease of use and cost commensurate with RDTs. Additionally, I am attaching an
executive summary describing the company. Our goal is to introduce Parasight's technology to the
Gates Foundation in hopes of advancing the project and reaching the target population.
As it happens, our co-founder and Chairman of the Scientific Advisory Board, Dr. Daniel Levner, is a Senior
Staff Scientist at Harvard Medical School, so perhaps the best way to present our technology would be
through a meeting. Please let me know what would be best for you.
Thanks,
Vossi Pollak
Chief Executive Officer
EFTA00967516